Wednesday, August 19, 2020

China grants country's first COVID-19 vaccine patent to CanSino



Tianjin: China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCoV, state media reported, citing documents from the country's intellectual property regulator.

It is the first COVID-19 vaccine patent granted by China, according to state-owned newspaper People's Daily. The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug. 11. A late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.
The Ad5-nCoV vaccine already has approval for use by China's military after early and mid-stage trials, and further late-stage trials are being lined up for Mexico and Saudi Arabia.

No comments:

Post a Comment

Spotlight

He said, "Sir, this is the Man," In the Blink of Eye, Dozen Armed Policemen Surrounded Us

He said, "Sir, this is the Man," In the Blink of Eye, Dozen Armed Policemen Surrounded Us
Kashmiri Journalist: He said, "Sir, this is the Man," In the Blink of Eye, Dozen Armed Policemen Surrounded Us

starlight

VOM SPECIAL : Seven Female Journalists who Married Star Cricketers

LIMELIGHT

Pages

flashlight

footlights